Geneticist, Albert Einstein College of Medicine
Israeli geneticist and longevity researcher at Albert Einstein College of Medicine who directs the Longevity Genes Project, a study of centenarians and their children. His group has identified gene variants linked to exceptional longevity, such as in CETP, APOC3 and IGF1R. He proposed metformin as a tool to target aging and is principal investigator of the planned TAME (Targeting Aging with Metformin) trial.
WHAT TO WATCHThe TAME trial, a double-blind, placebo-controlled study meant to test whether metformin delays multiple age-related diseases and to make the case for aging as an FDA indication.
A placebo-controlled trial in 145 older adults with glucose intolerance found metformin slowed a deficit-based frailty index, but not the Fried frailty score, and shifted two of 13 epigenetic clocks.
